XRTX
Xyratex Ltd.
NASDAQ · Healthcare · Biotechnology · CA
$1.01
−18.55%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 29.6K | — | 111.6K | — | — |
| Gross Profit | (29.6K) | — | (111.6K) | — | — |
| Operating Expenses | |||||
| R&D Expense | 259.8K | 574.9K | 175.0K | 2.4M | 9.2M |
| SG&A Expense | 3.2M | 1.8M | 3.6M | 2.2M | 3.3M |
| General & Admin Expense | 2.6M | 1.8M | — | 2.2M | 1.4M |
| Selling & Marketing Expense | — | — | — | — | 1.9M |
| Other Expenses | 452.9K | 849.4K | — | 1.4M | — |
| Total Operating Expenses | 3.9M | 3.3M | 3.8M | 6.0M | 12.4M |
| Cost and Expenses | 3.9M | 3.3M | 3.9M | 6.0M | 12.4M |
| Operating Income (EBIT) | (3.9M) | (3.3M) | (3.9M) | (6.0M) | (12.4M) |
| Non-Operating | |||||
| Interest Income | 15.5K | 41.9K | 116.1K | 253.5K | 140.3K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 15.5K | 41.9K | 116.1K | 253.5K | 140.3K |
| Other Non-Op Income/Expense | 178.9K | 599.7K | 766.3K | 3.9M | 2.0M |
| Non-Operating Income (excl Interest) | 84.00 | — | — | — | 78.7K |
| EBT (Pre-Tax Income) | (3.7M) | (2.7M) | (3.2M) | (2.2M) | (10.5M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (3.7M) | (2.7M) | (3.2M) | (2.2M) | (10.5M) |
| Earnings from Cont. Ops | (3.7M) | (2.7M) | (3.2M) | (2.2M) | (10.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (3.7M) | (2.7M) | (3.2M) | (2.2M) | (10.5M) |
| Per Share | |||||
| Basic EPS | ($2.74) | ($2.80) | ($5.48) | ($5.45) | ($176.55) |
| Diluted EPS | ($2.74) | ($2.80) | ($5.48) | ($5.45) | ($176.55) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.6M | 946926 | 575702 | 396346 | 59195 |
| Diluted Shares Outstanding | 1.6M | 946926 | 575702 | 396346 | 59195 |
| Profitability Metrics | |||||
| EBITDA | (3.8M) | (3.1M) | (3.8M) | (5.9M) | (12.4M) |
| D&A | 102.7K | 112.1K | 117.3K | 139.7K | 74.9K |
| EBIT | (3.9M) | (3.3M) | (3.9M) | (6.0M) | (12.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026